Cardiovascular Disease Biomarkers in Clinical Use and Their Modulation by Functional Foods

Author(s):  
Arpita Basu ◽  
Stacy Morris ◽  
Paramita Basu ◽  
Timothy J. Lyons
2007 ◽  
Vol 39 (5) ◽  
pp. S171-S178 ◽  
Author(s):  
Tricia L. Psota ◽  
Barbara Lohse ◽  
Sheila G. West

Author(s):  
Mikael Christiansen ◽  
Erik Lerkevang Grove ◽  
Anne-Mette Hvas

AbstractThe ability of aspirin to inhibit platelet aggregation has positioned this agent within the most frequently used drugs worldwide. The aim of this article is to review the contemporary clinical use of aspirin and also to discuss unresolved issues not yet translated into clinical practice. Results from several clinical trials have led to strong guideline recommendations for aspirin use in the acute management and secondary prevention of cardiovascular disease. On the contrary, guidelines regarding aspirin use as primary prevention of cardiovascular disease are almost conservative, supported by recent trials reporting that the bleeding risk outweighs the potential benefits in most patients. In pregnancy, aspirin has proved efficient in preventing preeclampsia and small-for-gestational-age births in women at high risk, and is hence widely recommended in clinical guidelines. Despite the vast amount of clinical data on aspirin, several unresolved questions remain. Randomized trials have reported that aspirin reduces the risk of recurrent venous thromboembolism, but the clinical relevance remains limited, because direct oral anticoagulants are more effective. Laboratory studies suggest that a twice-daily dosing regimen or evening intake may lead to more efficient platelet inhibition, and the potential clinical benefit of such strategies is currently being explored in ongoing clinical trials. Enteric-coated formulations of aspirin are frequently used, but it remains unclear if they are safer and as efficient as plain aspirin. In the future, aspirin use after percutaneous coronary interventions might not be mandatory in patients who also need anticoagulant therapy, as several trials support shorter aspirin duration strategies. On the other hand, new treatment indications for aspirin will likely arise, as there is growing evidence that aspirin may reduce the risk of colorectal cancer and other types of cancer.


SURG Journal ◽  
2019 ◽  
Vol 11 ◽  
Author(s):  
Maarij Siddiqi

While the impacts of modifiable and non-modifiable risk factors on chronic diseases such as cardiovascular disease (CVD) are widely established, the interactions between such coexisting risk factors and their subsequent effects on the promotion or suppression of CVD are less known. As part of the diet, functional foods are considered a modifiable factor that influence health beyond their basic nutritional value. The relationship between these functional foods and the underlying genome, along with their joint implication in health and disease, forms the focus of the emerging field of nutrigenomics. Reviewed in this paper are some prominent gene-diet interactions demonstrated in CVD etiology. Specifically, the interaction between foods such as phytosterols and isoflavones with genetic factors of the consuming population are examined in relation to CVD. By determining how nutritional intake affects genetics and vice versa, we create the potential to offer improved dietary guidelines to certain individuals, subgroups, or populations in order to maximize health benefits of specific diets.


2015 ◽  
Vol 27 (3) ◽  
pp. 167-173 ◽  
Author(s):  
Kristin M. Marano ◽  
Steven J. Kathman ◽  
Bobbette A. Jones ◽  
Brian K. Nordskog ◽  
Buddy G. Brown ◽  
...  

2019 ◽  
Vol 63 (3) ◽  
pp. 240-248
Author(s):  
Candice Y. Johnson ◽  
Lauren J. Tanz ◽  
Christina C. Lawson ◽  
Eva S. Schernhammer ◽  
Céline Vetter ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document